These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients. Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175 [TBL] [Abstract][Full Text] [Related]
10. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Jordan SC; Vo AA; Nast CC; Tyan D Clin Transpl; 2003; ():193-8. PubMed ID: 15387111 [TBL] [Abstract][Full Text] [Related]
11. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients. Duronio A; Bajjoka I; Hsaiky L; Parasuraman R Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157 [TBL] [Abstract][Full Text] [Related]
12. The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates. Taber T; Mujtaba MA; Goggins W; Higgins N; Sharfuddin A; Yaqub MS; Mishler D; Book B; Chen J; Lobashevsky A Clin Transplant; 2013; 27(4):E375-82. PubMed ID: 23721524 [TBL] [Abstract][Full Text] [Related]
13. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
14. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Ikegami T; Taketomi A; Soejima Y; Yoshizumi T; Uchiyama H; Harada N; Iguchi T; Hashimoto N; Maehara Y Transplantation; 2009 Aug; 88(3):303-7. PubMed ID: 19667930 [TBL] [Abstract][Full Text] [Related]
15. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Magee CC; Felgueiras J; Tinckam K; Malek S; Mah H; Tullius S Transplantation; 2008 Jul; 86(1):96-103. PubMed ID: 18622284 [TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127 [TBL] [Abstract][Full Text] [Related]
17. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible? Faenza A; Fuga G; Bertelli R; Scolari MP; Buscaroli A; Stefoni S Transplant Proc; 2008; 40(6):1833-8. PubMed ID: 18675064 [TBL] [Abstract][Full Text] [Related]
18. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Jordan S; Cunningham-Rundles C; McEwan R Am J Transplant; 2003 Jun; 3(6):653-64. PubMed ID: 12780556 [TBL] [Abstract][Full Text] [Related]
19. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925 [TBL] [Abstract][Full Text] [Related]